Improvements in adenoviral vector technology: Overcoming barriers for gene therapy

Clinical Genetics

Volumn 58, Issue 1, 2000, Pages 1-11

  Parks, Robin J ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Adenovirus; Gene therapy

Indexed keywords

DNA; VIRUS VECTOR;

ADENOVIRUS; GENE THERAPY; GENETIC TRANSDUCTION; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DNA, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 0033940906     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2000.580101.x     Document Type: Review

References (84)

1. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven Publishers, 1996: 2111-2148.
2. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997: 275: 1320-1323.
3. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. Embo J 1997: 16: 2294-2306.
4. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993: 73: 309-319.
5. Wickham TJ, Segal DM, Roelvink PW et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996: 70: 6831-6838.
6. Goldman M, Su Q, Wilson JM. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. Gene Ther 1996: 3: 811-818.
7. Mellman I. The importance of being acidic: the role of acidification in intracellular membrane traffic. J Exp Biol 1992: 172: 39-45.
8. Leopold PL, Ferris B, Grinberg I, Worgall S, Hackett NR, Crystal RG. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther 1998: 9: 367-378.
9. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993: 75: 477-486.
10. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977: 36: 59-74.
11. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993: 67: 5911-5921.
12. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992: 158: 39-66.
13. Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 1995: 6: 590-595.
14. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997: 40: 137-206.
15. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997: 8: 37-44.
16. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison, of E2a wild type and E2a deleted vectors. Hm Gene Ther 1997: 8: 1275-1286.
17. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994: 91: 4407-4411.
18. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998: 95: 11377-11382.
19. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996: 7: 1555-1566.
20. Lochmuller H, Petrof BJ, Pari G et al. Transient immuno-suppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther 1996: 3: 706-716.
21. Vilquin JT, Guerette B, Kinoshita I et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995: 6: 1391-1401.
22. Kolls JK, Lei D, Odom G et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996: 7: 489-497.
23. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 1997: 4: 309-316.
24. Sawchuk SJ, Boivin GP, Duwel LE et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum Gene Ther 1996: 7: 499-506.
25. Wolff G, Worgall S, van RN, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997: 71: 624-629.
26. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996: 3: 412-420.
27. Guerette B, Vilquin JT, Gingras M, Gravel C, Wood KJ, Tremblay JP. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996: 7: 1455-1463.
28. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998: 5: 309-319.
29. Schowalter DB, Meuse L, Wilson CB, Linsley PS, Kay MA. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. Gene Ther 1997: 4: 853-860.
30. Wilson CB, Embree LJ, Schowalter D et al. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J Virol 1998: 72: 7542-7550.
31. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996: 3: 154-162.
32. Zepeda M, Wilson JM. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors. Gene Ther 1996: 3: 973-979.
33. Lusky M, Christ M, Rittner K et al. In vitro and In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/ E2A, or E1/E4 deleted. J Virol 1998: 72: 2022-2032.
34. Fang B, Wang H, Gordon G et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 1996: 3: 217-222.
35. Amalfitano A, McVie-Wylie AJ, Hu H et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA 1999: 96: 8861-8866.
36. Hu H, Serra D, Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999: 10: 355-364.
37. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995: 92: 3854-3858.
38. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996: 217: 11-22.
39. Haecker SE, Stedman HH, Balice-Gordon RJ et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996: 7: 1907-1914.
40. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996: 5: 913-921.
41. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996: 93: 5731-5736.
42. Grable M, Hearing P. Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J Virol 1990: 64: 2047-2056.
43. Clemens PR, Kochanek S, Sunada Y et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 1996: 3: 965-972.
44. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997: 94: 1645-1650.
45. Chen HH, Mack LM, Choi SY, Ontell M, Kochanek S, Clemens PR. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999: 10: 365-373.
46. Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995: 6: 1291-1297.
47. Floyd SS Jr, Clemens PR, Ontell MR et al. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 1998: 5: 19-30.
48. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997: 71: 1842-1849.
49. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996: 70: 8944-8960.
50. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996: 93: 13565-13570.
51. Nelson JE, Kay MA. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J Virol 1997: 71: 8902-8907.
52. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 1996: 22: 477-488.
53. Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 1999: 73: 7835-7841.
54. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997: 71: 3293-3298.
55. Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol 1999: 73: 8027-8034.
56. Schiedner G, Morral N, Parks RJ et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998: 18: 180-183.
57. Pastore L, Morral N, Zhou H et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999: 10: 1773-1781.
58. Morral N, Parks RJ, Zhou H et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha 1-antitrypsin with negligible toxicity. Hum Gene Ther 1998: 9: 2709-2716.
59. Morral N, O'Neal W, Rice K et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999: 96: 12816-12821.
60. Morsy MA, Gu M, Motzel S et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998: 95: 7866-7871.
61. Alemany R, Dai Y, Lou YC et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods 1997: 68: 147-159.
62. Balague C, Zhou J, Dai Y et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000: 95: 820-828.
63. Dong JY, Wang D, Van GF, Pascual DW, Frizzell RA. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996: 7: 319-331.
64. St George J, Pennington SE, Kaplan JM et al. Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 1996: 3: 103-116.
65. Kaplan JM, St George J, Pennington SE et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 1996: 3: 117-127.
66. Parks RJ, Evelegh CM, Graham FL. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999: 6: 1565-1573.
67. Mack CA, Song WR, Carpenter H et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997: 8: 99-109.
68. Wickham TJ, Tzeng E, Shears LL et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997: 71: 8221-8229.
69. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999: 96: 355-360.
70. Recchia A, Parks RJ, Lamartina S et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 1999: 96: 2615-2620.
71. Snyder RO, Miao C, Meuse L et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999: 5: 64-70.
72. Tursz T, Cesne AL, Baldeyrou P et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996: 88: 1857-1863.
73. Stewart AK, Lassam NJ, Graham FL et al. A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum Gene Ther 1997: 8: 1403-1414.
74. Schuler M, Rochlitz C, Horowitz JA et al. A phase 1 study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998: 9: 2075-2082.
75. Roth JA, Swisher SG, Merritt JA et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase 1 trial of adenoviral p53 gene replacement. Semin Oncol 1998: 25: 33-37.
76. Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998: 9: 1083-1092.
77. Herman JR, Adler HL, Aguilar-Cordova E et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999: 10: 1239-1249.
78. Molnar-Kimber KL, Sterman DH, Chang M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998: 9: 2121-2133.
79. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993: 75: 207-216.
80. Bellon G, Michel-Calemard L, Thouvenot D et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997: 8: 15-25.
81. Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994: 8: 42-51.
82. Boucher RC, Knowles MR, Johnson LG et al. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum Gene Ther 1994: 5: 615-639.
83. Rosengart TK, Lee LY, Patel SR et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGFI21 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999: 100: 468-474.
84. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999: 286: 2244-2245.